Belite Bio (BLTE) Net Equity Issued and Repurchased (2024 - 2025)
Belite Bio's (BLTE) quarterly Net Equity Issued and Repurchased came in at $49.3 million in Q4 2025, up 417.13% year-on-year from $9.5 million in Q4 2024, and up 417.13% quarter-over-quarter from $9.5 million in Q4 2024.
Belite Bio (BLTE) Net Equity Issued and Repurchased (2024 - 2025) Analysis & Trends
Belite Bio's Net Equity Issued and Repurchased history runs 2 years deep, the most recent figure standing at $49.3 million for Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Equity Issued and Repurchased (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | - |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 163.10 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | 141.90 Mn |
| 10 | Alnylam Pharmaceuticals | 36.08 Bn | 33.07 Bn | 959.66 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 49.35 Mn |
| Dec 31, 2025 | 49.35 Mn |
| Dec 31, 2024 | 9.54 Mn |
| Dec 31, 2024 | 9.54 Mn |